• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

GE and Glaxo ally to develop molecular medicine

Article

GE Medical Systems has signed a broad collaborative research agreement with GlaxoSmithKline to bring clinical molecular imaging technologies into the pharmaceutical development process. Their first project will be to advance the diagnosis and treatment

GE Medical Systems has signed a broad collaborative research agreement with GlaxoSmithKline to bring clinical molecular imaging technologies into the pharmaceutical development process. Their first project will be to advance the diagnosis and treatment of chronic obstructive pulmonary disease (COPD). GE is aggressively pursuing noninvasive molecular imaging to detect and monitor disease with specific molecular markers. GlaxoSmithKline has expertise in respiratory science, molecular medicine, and drug development for diseases including COPD. Early research will be done at GE’s Corporate Research and Development site in Schenectady, NY, in collaboration with GlaxoSmithKline’s COPD Clinical Network. Together, the companies hope to develop new medicines and better means for diagnosing and treating COPD.

Recent Videos
Emerging Research at SNMMI Examines 18F-flotufolastat in Managing Primary and Recurrent Prostate Cancer
Could Pluvicto Have a Role in Taxane-Naïve mCRPC?: An Interview with Oliver Sartor, MD
New SNMMI President Cathy Cutler, PhD, Discusses Current Challenges and Goals for Nuclear Medicine
Where the USPSTF Breast Cancer Screening Recommendations Fall Short: An Interview with Stacy Smith-Foley, MD
A Closer Look at MRI-Guided Transurethral Ultrasound Ablation for Intermediate Risk Prostate Cancer
Improving the Quality of Breast MRI Acquisition and Processing
Can Fiber Optic RealShape (FORS) Technology Provide a Viable Alternative to X-Rays for Aortic Procedures?
Does Initial CCTA Provide the Best Assessment of Stable Chest Pain?
Making the Case for Intravascular Ultrasound Use in Peripheral Vascular Interventions
Can Diffusion Microstructural Imaging Provide Insights into Long Covid Beyond Conventional MRI?
Related Content
© 2024 MJH Life Sciences

All rights reserved.